PriceTargets.com logo

Can-Fite BioPharma - CANF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 661.42%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.97 As of 04/19/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CANF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Can-Fite BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CANF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CANF

Analyst Price Target is $15.00
▲ +661.42% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Can-Fite BioPharma in the last 3 months. The average price target is $15.00, with a high forecast of $18.00 and a low forecast of $12.00. The average price target represents a 661.42% upside from the last price of $1.97.

This chart shows the closing price for CANF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Can-Fite BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/24/2023HC WainwrightLower TargetBuy ➝ Buy$34.00 ➝ $18.00Low
7/24/2023Alliance Global PartnersBoost Target$8.25 ➝ $12.00Low
3/13/2023HC WainwrightReiterated RatingBuy$34.00N/A
1/3/2023Dawson JamesDowngradeBuy ➝ NeutralN/A
1/7/2022HC WainwrightReiterated RatingBuy$50.00N/A
11/30/2021Alliance Global PartnersLower TargetBuy$90.00 ➝ $82.50N/A
6/24/2021AegisInitiated CoverageBuy$50.00N/A
6/15/2021Alliance Global PartnersInitiated CoverageBuyN/A
2/26/2021HC WainwrightReiterated RatingBuyN/A
7/2/2020HC WainwrightReiterated RatingBuy$50.00N/A
5/18/2020HC WainwrightReiterated RatingBuy$50.00N/A
2/24/2020HC WainwrightReiterated RatingBuy$50.00N/A
10/31/2019HC WainwrightReiterated RatingBuy ➝ Positive$30.00 ➝ $50.00N/A
9/24/2019HC WainwrightLower TargetBuy$30.00N/A
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/23/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/22/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Can-Fite BioPharma logo
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Read More

Today's Range

Now: $1.97
Low: $1.97
High: $2.03

50 Day Range

MA: $2.16
Low: $1.96
High: $2.40

52 Week Range

Now: $1.97
Low: $1.66
High: $3.33

Volume

7,815 shs

Average Volume

19,783 shs

Market Capitalization

$6.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Can-Fite BioPharma?

The following equities research analysts have issued reports on Can-Fite BioPharma in the last year: Alliance Global Partners, HC Wainwright, and StockNews.com.
View the latest analyst ratings for CANF.

What is the current price target for Can-Fite BioPharma?

2 Wall Street analysts have set twelve-month price targets for Can-Fite BioPharma in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 661.4%. HC Wainwright has the highest price target set, predicting CANF will reach $18.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $12.00 for Can-Fite BioPharma in the next year.
View the latest price targets for CANF.

What is the current consensus analyst rating for Can-Fite BioPharma?

Can-Fite BioPharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CANF will outperform the market and that investors should add to their positions of Can-Fite BioPharma.
View the latest ratings for CANF.

What other companies compete with Can-Fite BioPharma?

Other companies that are similar to Can-Fite BioPharma include Tenax Therapeutics, Clever Leaves, Pulmatrix, Hillstream BioPharma and Pasithea Therapeutics. Learn More about companies similar to Can-Fite BioPharma.

How do I contact Can-Fite BioPharma's investor relations team?

Can-Fite BioPharma's physical mailing address is 10 Bareket Street, Kiryat Matalon PO Box 7537, Petah Tikva 4951778, Israel. The company's listed phone number is 972-3-924-1114 and its investor relations email address is [email protected]. The official website for Can-Fite BioPharma is www.canfite.com. Learn More about contacing Can-Fite BioPharma investor relations.